Characterization of a human bispecific antibody against CD20/CD55 for the treatment of burkitt lymphoma

被引：0
|
作者：
Macor, Paolo [1 ]
Mezzaroba, Nelly [1 ]
De Maso, Luca [1 ]
Garrovo, Chiara [2 ]
Biffi, Stefania [2 ]
Sblattero, Daniele [3 ]
Marzari, Roberto [1 ]
Tedesco, Francesco [1 ]
机构：
[1] Univ Trieste, Dept Life Sci, Trieste, Italy
[2] CBM, Opt Imaging Lab, Trieste, Italy
[3] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy
来源：
IMMUNOBIOLOGY | 2012年 / 217卷 / 11期
关键词：
D O I：
10.1016/j.imbio.2012.08.060
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
59
引用
收藏
页码：1149 / 1150
页数：2
相关论文
共 50 条
  • [1] Development of human bispecific antibodies against CD20/CD55 or CD20/CD59 for the treatment of Burkitt lymphoma
    Macor, P.
    Secco, E.
    Mezzaroba, N.
    De Maso, L.
    Durigutto, P.
    Gaiotto, T.
    Garrovo, C.
    Biffi, F.
    Zorzet, S.
    Sblattero, D.
    Tedesco, F.
    [J]. MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2287 - 2287
  • [2] Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    [J]. PLOS ONE, 2014, 9 (05):
  • [3] Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphoma
    Walsh, Frank S.
    Wicher, Krzysztof
    Szary, Jaroslaw
    Stocki, Pawel
    Demydchuk, Michael
    Rutkowski, Lynn
    [J]. CANCER RESEARCH, 2017, 77
  • [4] Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice
    Bongoni, Anjan K.
    Lu, Bo
    Salvaris, Evelyn J.
    Roberts, Veena
    Fang, Doreen
    Mcrae, Jennifer L.
    Fisicaro, Nella
    Dwyer, Karen M.
    Cowan, Peter J.
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (12): : 4837 - 4845
  • [5] Rituxan™:: Anti CD20 monoclonal antibody for the treatment of lymphoma.
    Grillo-López, AJ
    White, CA
    Dallaire, BK
    Varns, C
    Shen, D
    McClure, A
    [J]. EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 746 - 746
  • [6] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [7] A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
    Piccione, Emily C.
    Juarez, Silvia
    Liu, Jie
    Tseng, Serena
    Ryan, Christine E.
    Narayanan, Cyndhavi
    Wang, Lijuan
    Weiskopf, Kipp
    Majeti, Ravindra
    [J]. MABS, 2015, 7 (05) : 946 - 956
  • [8] Improved molecular design and immunization route of CD20 peptides induce antibody against human CD20 protein.
    Dao, T
    Antczak, C
    Boutsalis, G
    Kou, C
    Jaggi, J
    Kappel, B
    Pinilla-Ibarz, J
    Scheinberg, DA
    [J]. BLOOD, 2003, 102 (11) : 899A - 899A
  • [9] Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies
    Nalivaiko, Kristina
    Hofmann, Martin
    Grosse-Hovest, Ludger
    Krammer, Peter H.
    Rammensee, Hans-Georg
    Salih, Helmut R.
    Jung, Gundram
    [J]. BLOOD, 2011, 118 (21) : 510 - 510
  • [10] Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)
    Nakagawa, Y
    Ikeda, U
    Hirose, M
    Ubukata, S
    Katsuki, T
    Kaminishi, Y
    Saito, T
    Hironaka, M
    Izumi, T
    Shimada, K
    [J]. CIRCULATION JOURNAL, 2004, 68 (02) : 172 - 173
12345